The role of histone deacetylases (HDACs) in human cancer

The balance of histone acetylation and deacetylation is an epigenetic layer with a critical role in the regulation of gene expression. Histone acetylation induced by histone acetyl transferases (HATs) is associated with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is associated with gene silencing. Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell‐cycle regulation and apoptosis. Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.

[1]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  Masayoshi Iizuka,et al.  Functional consequences of histone modifications. , 2003, Current opinion in genetics & development.

[4]  L. Magnaghi-Jaulin,et al.  The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[6]  D. Reinberg,et al.  Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. , 2004, Molecular cell.

[7]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[8]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[9]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[10]  M. Esteller,et al.  Histone deacetylase inhibitors: Understanding a new wave of anticancer agents , 2004, International journal of cancer.

[11]  T. Toyama,et al.  HDAC 6 Expression Is Correlated with Better Survival in Breast Cancer , 2004 .

[12]  L. Aaltonen,et al.  A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition , 2006, Nature Genetics.

[13]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[14]  K. Ghoshal,et al.  DNA Methyltransferase 3b Regulates Nerve Growth Factor-Induced Differentiation of PC12 Cells by Recruiting Histone Deacetylase 2 , 2005, Molecular and Cellular Biology.

[15]  Takeshi Inoue,et al.  Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. , 2003, Biochemical pharmacology.

[16]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  S. Baylin,et al.  Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses , 2005, Cell.

[18]  V. P. Collins,et al.  Differential expression of selected histone modifier genes in human solid cancers , 2006, BMC Genomics.

[19]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[20]  R. Evans,et al.  Transcriptional regulation in acute promyelocytic leukemia , 2001, Oncogene.

[21]  E. Fearon,et al.  Cadherin and catenin alterations in human cancer , 2002, Genes, chromosomes & cancer.

[22]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[23]  D. Qian,et al.  Targeting TumorAngiogenesis with Histone Deacetylase Inhibitors : the Hydroxamic Acid Derivative LBH 589 , 2006 .

[24]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[25]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[27]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[28]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[29]  Hiroko Yamashita,et al.  HDAC6 Expression Is Correlated with Better Survival in Breast Cancer , 2004, Clinical Cancer Research.

[30]  H. Kawai,et al.  Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α , 2003, International journal of cancer.

[31]  G. Christofori,et al.  The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. , 1999, Trends in biochemical sciences.

[32]  M. Fraga,et al.  Human DNA Methyltransferase 1 Is Required for Maintenance of the Histone H3 Modification Pattern* , 2004, Journal of Biological Chemistry.

[33]  H. Kwon,et al.  Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.

[34]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[35]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[36]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[37]  S. Tucker,et al.  Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.

[38]  N. Pattabiraman,et al.  Hormonal Control of Androgen Receptor Function through SIRT1 , 2006, Molecular and Cellular Biology.

[39]  E. Knudsen,et al.  Histone Deacetylation of RB-Responsive Promoters: Requisite for Specific Gene Repression but Dispensable for Cell Cycle Inhibition , 2003, Molecular and Cellular Biology.

[40]  M. Oshimura,et al.  Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.

[41]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[42]  Hsiang-Yu Lin,et al.  Targeting histone deacetylase in cancer therapy , 2006, Medicinal research reviews.

[43]  David P. Toczyski,et al.  Complicated Tails: Histone Modifications and the DNA Damage Response , 2005, Cell.

[44]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[45]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[46]  G. Almouzni,et al.  Histone metabolic pathways and chromatin assembly factors as proliferation markers. , 2005, Cancer letters.

[47]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[48]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[49]  W. Gu,et al.  SIRT1 Deacetylation and Repression of p300 Involves Lysine Residues 1020/1024 within the Cell Cycle Regulatory Domain 1* , 2005, Journal of Biological Chemistry.

[50]  Kelly M. McGarvey,et al.  Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation , 2006, PLoS genetics.

[51]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[52]  Wen‐Ming Yang,et al.  Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation* , 2000, The Journal of Biological Chemistry.

[53]  N. Dyson,et al.  Molecular mechanisms of E2F-dependent activation and pRB-mediated repression , 2004, Journal of Cell Science.

[54]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[55]  C. Bradbury,et al.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors , 2005, Leukemia.

[56]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[57]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[59]  Caterina Cinti,et al.  pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-α in breast cancer , 2003, Oncogene.

[60]  K. Furge,et al.  Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. , 2004, International journal of oncology.

[61]  W. Gu,et al.  Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage , 2006, Nature Cell Biology.

[62]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[63]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.